COVID-19 is associated with high mortality in patients with haematological malignancies (HM) and rate of seroconversion is unknown. The ITA-HEMA-COV project (NCT04352556) investigated patterns of seroconversion for SARS-CoV-2 IgG in patients with HMs. A total of 237 patients, SARS-CoV-2 PCR-positive with at least one SARS-CoV-2 IgG test performed during their care, entered the analysis. Among these, 62 (26·2%) had myeloid, 121 (51·1%) lymphoid and 54 (22·8%) plasma cell neoplasms. Overall, 69% of patients (164 of 237) had detectable IgG SARS-CoV-2 serum antibodies. Serologically negative patients (31%, 73 of 237) were evenly distributed across patients with myeloid, lymphoid and plasma cell neoplasms. In the multivariable logistic regression, chemoimmunotherapy [odds ratio (OR), 3·42; 95% confidence interval (CI), 1·04-11·21; P = 0·04] was associated with a lower rate of seroconversion. This effect did not decline after 180 days from treatment withdrawal (OR, 0·35; 95% CI: 0·11-1·13; P = 0·08). This study demonstrates a low rate of seroconversion in HM patients and indicates that treatment-mediated immune dysfunction is the main driver. As a consequence, we expect a low rate of seroconversion after vaccination and thus we suggest testing the efficacy of seroconversion in HM patients.

COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies / Passamonti, Francesco; Romano, Alessandra; Salvini, Marco; Merli, Francesco; Porta, Matteo G Della; Bruna, Riccardo; Coviello, Elisa; Romano, Ilaria; Cairoli, Roberto; Lemoli, Roberto; Farina, Francesca; Venditti, Adriano; Busca, Alessandro; Ladetto, Marco; Massaia, Massimo; Pinto, Antonio; Arcaini, Luca; Tafuri, Agostino; Marchesi, Francesco; Fracchiolla, Nicola; Bocchia, Monica; Armiento, Daniele; Candoni, Anna; Krampera, Mauro; Luppi, Mario; Cardinali, Valeria; Galimberti, Sara; Cattaneo, Chiara; La Barbera, Elettra Ortu; Mina, Roberto; Lanza, Francesco; Visani, Giuseppe; Musto, Pellegrino; Petrucci, Luigi; Zaja, Francesco; Grossi, Paolo A; Bertù, Lorenza; Pagano, Livio; Corradini, Paolo; ITA-HEMA-COV Investigators*: Enrico Derenzini, Monia Marchetti, Anna M Scattolin, Alessandro Corso, Patrizia Tosi, Filippo Gherlinzoni, Carlo Gambacorti Passerini, Michele Cavo, Carmen Fava, Mauro Turrini, Carlo Visco, Patrizia Zappasodi, Michele Merli, Barbara Mora, Alessandro M Vannucchi. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 1365-2141. - ELETTRONICO. - 195:(2021), pp. 371-377. [10.1111/bjh.17704]

COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies

Romano, Ilaria;Alessandro M Vannucchi
2021

Abstract

COVID-19 is associated with high mortality in patients with haematological malignancies (HM) and rate of seroconversion is unknown. The ITA-HEMA-COV project (NCT04352556) investigated patterns of seroconversion for SARS-CoV-2 IgG in patients with HMs. A total of 237 patients, SARS-CoV-2 PCR-positive with at least one SARS-CoV-2 IgG test performed during their care, entered the analysis. Among these, 62 (26·2%) had myeloid, 121 (51·1%) lymphoid and 54 (22·8%) plasma cell neoplasms. Overall, 69% of patients (164 of 237) had detectable IgG SARS-CoV-2 serum antibodies. Serologically negative patients (31%, 73 of 237) were evenly distributed across patients with myeloid, lymphoid and plasma cell neoplasms. In the multivariable logistic regression, chemoimmunotherapy [odds ratio (OR), 3·42; 95% confidence interval (CI), 1·04-11·21; P = 0·04] was associated with a lower rate of seroconversion. This effect did not decline after 180 days from treatment withdrawal (OR, 0·35; 95% CI: 0·11-1·13; P = 0·08). This study demonstrates a low rate of seroconversion in HM patients and indicates that treatment-mediated immune dysfunction is the main driver. As a consequence, we expect a low rate of seroconversion after vaccination and thus we suggest testing the efficacy of seroconversion in HM patients.
195
371
377
Passamonti, Francesco; Romano, Alessandra; Salvini, Marco; Merli, Francesco; Porta, Matteo G Della; Bruna, Riccardo; Coviello, Elisa; Romano, Ilaria; Cairoli, Roberto; Lemoli, Roberto; Farina, Francesca; Venditti, Adriano; Busca, Alessandro; Ladetto, Marco; Massaia, Massimo; Pinto, Antonio; Arcaini, Luca; Tafuri, Agostino; Marchesi, Francesco; Fracchiolla, Nicola; Bocchia, Monica; Armiento, Daniele; Candoni, Anna; Krampera, Mauro; Luppi, Mario; Cardinali, Valeria; Galimberti, Sara; Cattaneo, Chiara; La Barbera, Elettra Ortu; Mina, Roberto; Lanza, Francesco; Visani, Giuseppe; Musto, Pellegrino; Petrucci, Luigi; Zaja, Francesco; Grossi, Paolo A; Bertù, Lorenza; Pagano, Livio; Corradini, Paolo; ITA-HEMA-COV Investigators*: Enrico Derenzini, Monia Marchetti, Anna M Scattolin, Alessandro Corso, Patrizia Tosi, Filippo Gherlinzoni, Carlo Gambacorti Passerini, Michele Cavo, Carmen Fava, Mauro Turrini, Carlo Visco, Patrizia Zappasodi, Michele Merli, Barbara Mora, Alessandro M Vannucchi
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2158/1287000
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 28
  • ???jsp.display-item.citation.isi??? ND
social impact